digraph G {
  rankdir=LR;
  node [style=filled];
  "Inquire about known high-risk germline mutations" [label="Inquire about known high-risk germline mutations", fillcolor="#ADD8E6"];
  "Regional prostate cancer" [label="Regional prostate cancer", fillcolor="#FFA500"];
  "Inquire about family history" [label="Inquire about family history", fillcolor="#FFA500"];
  "Initial Risk Stratification" [label="Initial Risk Stratification", fillcolor="#ADD8E6"];
  "Clinically Localized Disease" [label="Clinically Localized Disease", fillcolor="#90EE90"];
  "Very low risk group" [label="Very low risk group", fillcolor="#ADD8E6"];
  "cT1c" [label="cT1c", fillcolor="#90EE90"];
  "Grade Group 1" [label="Grade Group 1", fillcolor="#FFA500"];
  "PSA <10 ng/mL" [label="PSA <10 ng/mL", fillcolor="#FFA500"];
  "<3 prostate biopsy fragments/cores positive" [label="<3 prostate biopsy fragments/cores positive", fillcolor="#90EE90"];
  "≤50% cancer in each fragment/core" [label="≤50% cancer in each fragment/core", fillcolor="#90EE90"];
  "PSA density <0.15 ng/mL/g" [label="PSA density <0.15 ng/mL/g", fillcolor="#90EE90"];
  "Confirmatory testing" [label="Confirmatory testing", fillcolor="#FFA500"];
  "PROS-3" [label="PROS-3", fillcolor="#90EE90"];
  "Low risk group" [label="Low risk group", fillcolor="#FFA500"];
  "cT1–cT2a" [label="cT1–cT2a", fillcolor="#90EE90"];
  "Very low risk" [label="Very low risk", fillcolor="#90EE90"];
  "PROS-4" [label="PROS-4", fillcolor="#90EE90"];
  "Intermediate risk group" [label="Intermediate risk group", fillcolor="#ADD8E6"];
  "Favorable intermediate" [label="Favorable intermediate", fillcolor="#90EE90"];
  "Unfavorable intermediate" [label="Unfavorable intermediate", fillcolor="#90EE90"];
  "High risk group" [label="High risk group", fillcolor="#ADD8E6"];
  "cT3a OR" [label="cT3a OR", fillcolor="#90EE90"];
  "Grade Group 4 or Grade Group 5 OR" [label="Grade Group 4 or Grade Group 5 OR", fillcolor="#90EE90"];
  "PSA >20 ng/mL" [label="PSA >20 ng/mL", fillcolor="#90EE90"];
  "Bone and soft tissue imaging" [label="Bone and soft tissue imaging", fillcolor="#FFA500"];
  "PROS-7" [label="PROS-7", fillcolor="#FFA500"];
  "Very high risk group" [label="Very high risk group", fillcolor="#FFA500"];
  "cT3b–cT4" [label="cT3b–cT4", fillcolor="#90EE90"];
  "Primary Gleason pattern 5" [label="Primary Gleason pattern 5", fillcolor="#90EE90"];
  "2 or 3 high-risk features" [label="2 or 3 high-risk features", fillcolor="#90EE90"];
  ">4 cores with Grade Group 4 or 5" [label=">4 cores with Grade Group 4 or 5", fillcolor="#90EE90"];
  "Favorable intermediate risk group" [label="Favorable intermediate risk group", fillcolor="#FFA500"];
  "PROS-5" [label="PROS-5", fillcolor="#90EE90"];
  "Unfavorable intermediate risk group" [label="Unfavorable intermediate risk group", fillcolor="#FFA500"];
  "PROS-6" [label="PROS-6", fillcolor="#90EE90"];
  "If regional or distant metastases are found" [label="If regional or distant metastases are found", fillcolor="#90EE90"];
  "See PROS-8 or PROS-13" [label="See PROS-8 or PROS-13", fillcolor="#90EE90"];
  "Very-low-risk group" [label="Very-low-risk group", fillcolor="#ADD8E6"];
  "Active surveillance" [label="Active surveillance", fillcolor="#90EE90"];
  "Observation" [label="Observation", fillcolor="#90EE90"];
  "Progressive disease" [label="Progressive disease", fillcolor="#ADD8E6"];
  "See Initial Risk Stratification and Staging Workup for Clinically Localized Disease (PROS-2)" [label="See Initial Risk Stratification and Staging Workup for Clinically Localized Disease (PROS-2)", fillcolor="#90EE90"];
  "Footnote s" [label="Footnote s", fillcolor="#90EE90"];
  "Clinically localized prostate cancer" [label="Clinically localized prostate cancer", fillcolor="#FFA500"];
  "See Initial Risk Stratification and Staging Workup for Clinically Localized Disease [PROS-2]" [label="See Initial Risk Stratification and Staging Workup for Clinically Localized Disease [PROS-2]", fillcolor="#90EE90"];
  "PSMA-PET/CT" [label="PSMA-PET/CT", fillcolor="#ADD8E6"];
  "Bone and soft tissue (full body) imaging" [label="Bone and soft tissue (full body) imaging", fillcolor="#FFA500"];
  "PSMA-PET/MRI" [label="PSMA-PET/MRI", fillcolor="#90EE90"];
  "Equivocal results" [label="Equivocal results", fillcolor="#ADD8E6"];
  "Soft tissue imaging of the pelvis" [label="Soft tissue imaging of the pelvis", fillcolor="#90EE90"];
  "PSMA-PET" [label="PSMA-PET", fillcolor="#ADD8E6"];
  "Not a necessary prerequisite" [label="Not a necessary prerequisite", fillcolor="#90EE90"];
  "Footnote d" [label="Footnote d", fillcolor="#ADD8E6"];
  "Principles of Genetics and Molecular/Biomarker Analysis (PROS-C)" [label="Principles of Genetics and Molecular/Biomarker Analysis (PROS-C)", fillcolor="#90EE90"];
  "Footnote e" [label="Footnote e", fillcolor="#ADD8E6"];
  "Principles of Quality-of-Life and Shared Decision-Making (PROS-D)" [label="Principles of Quality-of-Life and Shared Decision-Making (PROS-D)", fillcolor="#90EE90"];
  "Footnote l" [label="Footnote l", fillcolor="#ADD8E6"];
  "Percentage of positive cores in the intermediate-risk group" [label="Percentage of positive cores in the intermediate-risk group", fillcolor="#90EE90"];
  "Metastatic prostate cancer" [label="Metastatic prostate cancer", fillcolor="#ADD8E6"];
  "Any T, Any N, M1" [label="Any T, Any N, M1", fillcolor="#90EE90"];
  "Systemic Therapy for M1 Castration-Sensitive Prostate Cancer (CSPC) [PROS-13]" [label="Systemic Therapy for M1 Castration-Sensitive Prostate Cancer (CSPC) [PROS-13]", fillcolor="#90EE90"];
  "See Regional Prostate Cancer [PROS-8]" [label="See Regional Prostate Cancer [PROS-8]", fillcolor="#90EE90"];
  "Inquire about known high-risk germline mutations" -> "Regional prostate cancer" [label="requires workup\nrequires\n(Doc: doc1)", color="#543f7f"];
  "Inquire about known high-risk germline mutations" -> "Clinically localized prostate cancer" [label="requires workup\nrequires\n(Doc: doc1)", color="#543f7f"];
  "Regional prostate cancer" -> "Inquire about family history" [label="requires workup\nrequires\n(Doc: doc1)", color="#543f7f"];
  "Inquire about family history" -> "Clinically localized prostate cancer" [label="requires workup\nrequires\n(Doc: doc1)", color="#543f7f"];
  "Initial Risk Stratification" -> "Clinically Localized Disease" [label="for\nis used for\n(Doc: doc1)", color="#7f6a3f"];
  "Very low risk group" -> "cT1c" [label="has all of\nincludes\n(Doc: doc1)", color="#6a7f3f"];
  "Very low risk group" -> "Grade Group 1" [label="has all of\nincludes\n(Doc: doc1)", color="#6a7f3f"];
  "Very low risk group" -> "PSA <10 ng/mL" [label="has all of\nincludes\n(Doc: doc1)", color="#6a7f3f"];
  "Very low risk group" -> "<3 prostate biopsy fragments/cores positive" [label="has all of\nincludes\n(Doc: doc1)", color="#6a7f3f"];
  "Very low risk group" -> "≤50% cancer in each fragment/core" [label="has all of\nincludes\n(Doc: doc1)", color="#6a7f3f"];
  "Very low risk group" -> "PSA density <0.15 ng/mL/g" [label="has all of\nincludes\n(Doc: doc1)", color="#6a7f3f"];
  "Very low risk group" -> "Confirmatory testing" [label="additional evaluation\nrequires\n(Doc: doc1)", color="#7f3f6a"];
  "Very low risk group" -> "PROS-3" [label="initial therapy\nrefers to\n(Doc: doc1)", color="#6a3f7f"];
  "Grade Group 1" -> "Low risk group" [label="has all of\nincludes\n(Doc: doc1)", color="#6a7f3f"];
  "PSA <10 ng/mL" -> "Low risk group" [label="has all of\nincludes\n(Doc: doc1)", color="#6a7f3f"];
  "Confirmatory testing" -> "Low risk group" [label="additional evaluation\nrequires\n(Doc: doc1)", color="#7f3f6a"];
  "Confirmatory testing" -> "Favorable intermediate risk group" [label="additional evaluation\nrequires\n(Doc: doc1)", color="#7f3f6a"];
  "Low risk group" -> "cT1–cT2a" [label="has all of\nincludes\n(Doc: doc1)", color="#6a7f3f"];
  "Low risk group" -> "Very low risk" [label="does not qualify for\nis distinct from\n(Doc: doc1)", color="#3f7f55"];
  "Low risk group" -> "PROS-4" [label="initial therapy\nrefers to\n(Doc: doc1)", color="#6a3f7f"];
  "Intermediate risk group" -> "Favorable intermediate" [label="has\nincludes\n(Doc: doc1)", color="#7f3f3f"];
  "Intermediate risk group" -> "Unfavorable intermediate" [label="has\nincludes\n(Doc: doc1)", color="#7f3f3f"];
  "High risk group" -> "cT3a OR" [label="has\nincludes\n(Doc: doc1)", color="#7f3f3f"];
  "High risk group" -> "Grade Group 4 or Grade Group 5 OR" [label="has\nincludes\n(Doc: doc1)", color="#7f3f3f"];
  "High risk group" -> "PSA >20 ng/mL" [label="has\nincludes\n(Doc: doc1)", color="#7f3f3f"];
  "High risk group" -> "Bone and soft tissue imaging" [label="additional evaluation\nrequires\n(Doc: doc1)", color="#7f3f6a"];
  "High risk group" -> "PROS-7" [label="initial therapy\nrefers to\n(Doc: doc1)", color="#6a3f7f"];
  "Bone and soft tissue imaging" -> "Very high risk group" [label="additional evaluation\nrequires\n(Doc: doc1)", color="#7f3f6a"];
  "Bone and soft tissue imaging" -> "Unfavorable intermediate risk group" [label="additional evaluation\nrequires\n(Doc: doc1)", color="#7f3f6a"];
  "Bone and soft tissue imaging" -> "If regional or distant metastases are found" [label="condition\nis performed\n(Doc: doc1)", color="#7f3f7f"];
  "Bone and soft tissue imaging" -> "See PROS-8 or PROS-13" [label="next step if metastases found\nleads to\n(Doc: doc1)", color="#3f7f6a"];
  "PROS-7" -> "Very high risk group" [label="initial therapy\nrefers to\n(Doc: doc1)", color="#6a3f7f"];
  "Very high risk group" -> "cT3b–cT4" [label="has at least one of\nincludes\n(Doc: doc1)", color="#3f6a7f"];
  "Very high risk group" -> "Primary Gleason pattern 5" [label="has at least one of\nincludes\n(Doc: doc1)", color="#3f6a7f"];
  "Very high risk group" -> "2 or 3 high-risk features" [label="has at least one of\nincludes\n(Doc: doc1)", color="#3f6a7f"];
  "Very high risk group" -> ">4 cores with Grade Group 4 or 5" [label="has at least one of\nincludes\n(Doc: doc1)", color="#3f6a7f"];
  "Favorable intermediate risk group" -> "PROS-5" [label="initial therapy\nrefers to\n(Doc: doc1)", color="#6a3f7f"];
  "Unfavorable intermediate risk group" -> "PROS-6" [label="initial therapy\nrefers to\n(Doc: doc1)", color="#6a3f7f"];
  "Very-low-risk group" -> "Active surveillance" [label="expected patient survival ≥10 y\nrecommends\n(Doc: doc1)", color="#7f7f3f"];
  "Very-low-risk group" -> "Observation" [label="expected patient survival <10 y\nrecommends\n(Doc: doc1)", color="#3f3f7f"];
  "Progressive disease" -> "See Initial Risk Stratification and Staging Workup for Clinically Localized Disease (PROS-2)" [label="next step\nproceeds to\n(Doc: doc1)", color="#3f7f3f"];
  "Progressive disease" -> "Footnote s" [label="refers to\ndescribes\n(Doc: doc1)", color="#557f3f"];
  "Clinically localized prostate cancer" -> "See Initial Risk Stratification and Staging Workup for Clinically Localized Disease [PROS-2]" [label="next step\nproceeds to\n(Doc: doc1)", color="#3f7f3f"];
  "PSMA-PET/CT" -> "Bone and soft tissue (full body) imaging" [label="can be considered for\nis used for\n(Doc: doc1)", color="#7f553f"];
  "Bone and soft tissue (full body) imaging" -> "PSMA-PET/MRI" [label="can be considered for\nis used for\n(Doc: doc1)", color="#7f553f"];
  "Equivocal results" -> "Soft tissue imaging of the pelvis" [label="require\nnecessitates\n(Doc: doc1)", color="#7f3f55"];
  "PSMA-PET" -> "Not a necessary prerequisite" [label="use\nis considered\n(Doc: doc1)", color="#3f547f"];
  "Footnote d" -> "Principles of Genetics and Molecular/Biomarker Analysis (PROS-C)" [label="refers to\nreferences\n(Doc: doc1)", color="#557f3f"];
  "Footnote e" -> "Principles of Quality-of-Life and Shared Decision-Making (PROS-D)" [label="refers to\nreferences\n(Doc: doc1)", color="#557f3f"];
  "Footnote l" -> "Percentage of positive cores in the intermediate-risk group" [label="refers to\ndescribes\n(Doc: doc1)", color="#557f3f"];
  "Metastatic prostate cancer" -> "Any T, Any N, M1" [label="defined as\nis defined as\n(Doc: doc1)", color="#3f7f7f"];
  "Metastatic prostate cancer" -> "Systemic Therapy for M1 Castration-Sensitive Prostate Cancer (CSPC) [PROS-13]" [label="next step\nproceeds to\n(Doc: doc1)", color="#3f7f3f"];
  "Metastatic prostate cancer" -> "See Regional Prostate Cancer [PROS-8]" [label="next step\nproceeds to\n(Doc: doc1)", color="#3f7f3f"];
  subgraph cluster_legend {
    label = "Legend";
    node [shape=box];
    "Subject" [fillcolor="#ADD8E6"];
    "Object" [fillcolor="#90EE90"];
    "Both" [fillcolor="#FFA500"];
    "has" [shape=plaintext, fillcolor="white"];
    "dummy_has" [shape=point, style=invis];
    "dummy_has" -> "has" [color="#7f3f3f"];
    "can be considered for" [shape=plaintext, fillcolor="white"];
    "dummy_can be considered for" [shape=point, style=invis];
    "dummy_can be considered for" -> "can be considered for" [color="#7f553f"];
    "for" [shape=plaintext, fillcolor="white"];
    "dummy_for" [shape=point, style=invis];
    "dummy_for" -> "for" [color="#7f6a3f"];
    "expected patient survival ≥10 y" [shape=plaintext, fillcolor="white"];
    "dummy_expected patient survival ≥10 y" [shape=point, style=invis];
    "dummy_expected patient survival ≥10 y" -> "expected patient survival ≥10 y" [color="#7f7f3f"];
    "has all of" [shape=plaintext, fillcolor="white"];
    "dummy_has all of" [shape=point, style=invis];
    "dummy_has all of" -> "has all of" [color="#6a7f3f"];
    "refers to" [shape=plaintext, fillcolor="white"];
    "dummy_refers to" [shape=point, style=invis];
    "dummy_refers to" -> "refers to" [color="#557f3f"];
    "next step" [shape=plaintext, fillcolor="white"];
    "dummy_next step" [shape=point, style=invis];
    "dummy_next step" -> "next step" [color="#3f7f3f"];
    "does not qualify for" [shape=plaintext, fillcolor="white"];
    "dummy_does not qualify for" [shape=point, style=invis];
    "dummy_does not qualify for" -> "does not qualify for" [color="#3f7f55"];
    "next step if metastases found" [shape=plaintext, fillcolor="white"];
    "dummy_next step if metastases found" [shape=point, style=invis];
    "dummy_next step if metastases found" -> "next step if metastases found" [color="#3f7f6a"];
    "defined as" [shape=plaintext, fillcolor="white"];
    "dummy_defined as" [shape=point, style=invis];
    "dummy_defined as" -> "defined as" [color="#3f7f7f"];
    "has at least one of" [shape=plaintext, fillcolor="white"];
    "dummy_has at least one of" [shape=point, style=invis];
    "dummy_has at least one of" -> "has at least one of" [color="#3f6a7f"];
    "use" [shape=plaintext, fillcolor="white"];
    "dummy_use" [shape=point, style=invis];
    "dummy_use" -> "use" [color="#3f547f"];
    "expected patient survival <10 y" [shape=plaintext, fillcolor="white"];
    "dummy_expected patient survival <10 y" [shape=point, style=invis];
    "dummy_expected patient survival <10 y" -> "expected patient survival <10 y" [color="#3f3f7f"];
    "requires workup" [shape=plaintext, fillcolor="white"];
    "dummy_requires workup" [shape=point, style=invis];
    "dummy_requires workup" -> "requires workup" [color="#543f7f"];
    "initial therapy" [shape=plaintext, fillcolor="white"];
    "dummy_initial therapy" [shape=point, style=invis];
    "dummy_initial therapy" -> "initial therapy" [color="#6a3f7f"];
    "condition" [shape=plaintext, fillcolor="white"];
    "dummy_condition" [shape=point, style=invis];
    "dummy_condition" -> "condition" [color="#7f3f7f"];
    "additional evaluation" [shape=plaintext, fillcolor="white"];
    "dummy_additional evaluation" [shape=point, style=invis];
    "dummy_additional evaluation" -> "additional evaluation" [color="#7f3f6a"];
    "require" [shape=plaintext, fillcolor="white"];
    "dummy_require" [shape=point, style=invis];
    "dummy_require" -> "require" [color="#7f3f55"];
  }
}